Abstract: The disclosure provides anti-DENV antibodies having a cross-reactivity to ZIKV and methods of making and using the same. The anti-DENV antibodies have uses that include treating or preventing ZIKV infection.

Abstract: There is provided a method of identifying/characterising coronavirus infection in a human subject. In a specific embodiment the method comprising contacting a serum sample from the subject with an isolated host cell expressing a nucleotide that encodes for a codon optimised gene for SARS-CoV-2 spike protein (S protein); and detecting a binding of an antibody or an antigen-binding fragment thereof to said host cell using a flow cytometry and a labelled anti-human secondary antibody. Also disclosed is a method of identifying a subject having immunity for coronavirus, especially SARS-CoV-2 wherein a sample from a subject is incubated with said cell and is detected using the flow cytometry and the labelled anti-human secondary antibody. Nucleic acid encoding a SARS-CoV-2 S protein, viral vectors and host cells thereof are also disclosed.

Abstract: There is provided a method of evaluating risk of severe outcome of an infectious disease and/or an inflammatory disease in a patient, the method comprising: determining/measuring the number of one or more immune cells selected from the group consisting of VD2 T cells, CD8 T cells, and immature neutrophils in a sample obtained from the patient, wherein the patient has an enhanced risk of severe infectious disease and/or inflammatory disease outcome when: (i) the ratio of immature neutrophils to VD2 T cell is at least 2:1, and/or (ii) the ratio of immature neutrophils to CD8 T cell is at least 0.5:1. Also disclosed are method of treating a patient with a severe infectious disease and/or inflammatory disease and kit for use in methods thereof.

Abstract: The invention relates to a composition comprising insulin growth factor binding protein 7 (IGFBP7) for treating malaria or reducing the phenomenon of IRB C-endothelial cytoadherence. The composition can further comprise Von Willebrand Factor (VWF) and/or thrombospondin-1 (TSP-1). The composition can also be used as an adjunct therapeutic agent alongside other anti-malarial drugs.

Abstract: The disclosure provides anti-DENV antibodies having a cross-reactivity to ZIKV and methods of making and using the same. The anti-DENV antibodies have uses that include treating or preventing ZIKV infection.

Abstract: The present invention relates to various novel substituted dipeptide derived nitrogen-containing heterocyclic compounds, their pharmaceutically acceptable salt derivatives, and their methods of use. In one aspect the present invention relates to compositions and methods for the treatment and prevention of disease in a mammal comprising administering the compounds of the invention in a pharmaceutically acceptable form to a mammal. In particular, the invention relates to medicaments comprising various novel substituted dipeptide derived nitrogen-containing heterocyclic compounds and pharmaceutically acceptable salt derivatives and methods for administration to a mammal for the treatment and prevention of malarial diseases. The compounds of the invention may optionally be administered with at least one pharmaceutically acceptable excipient, another biologically active agent or a combination thereof.

Abstract: The present invention relates to various novel substituted dipeptide derived nitrogen-containing heterocyclic compounds, their pharmaceutically acceptable salt derivatives, and their methods of use. In one aspect the present invention relates to compositions and methods for the treatment and prevention of disease in a mammal comprising administering the compounds of the invention in a pharmaceutically acceptable form to a mammal. In particular, the invention relates to medicaments comprising various novel substituted dipeptide derived nitrogen-containing heterocyclic compounds and pharmaceutically acceptable salt derivatives and methods for administration to a mammal for the treatment and prevention of malarial diseases. The compounds of the invention may optionally be administered with at least one pharmaceutically acceptable excipient, another biologically active agent or a combination thereof.

Abstract: Methods for the synthesis of various novel substituted dipeptide derived nitrogen-containing heterocyclic compounds and their pharmaceutically acceptable salt derivatives are provided. The compounds of the invention are useful as medicaments for the treatment or prevention of disease in a mammal, for example a human. In particular the compounds are useful as immunotherapeutics and anti-microbial drugs or vaccines. These heterocyclic derivatives can be used as an active agent in a pharmaceutical, as well as a diagnostic utility.

Abstract: The present invention relates to various novel substituted dipeptide derived nitrogen-containing heterocyclic compounds, their pharmaceutically acceptable salt derivatives, and their methods of use. In one aspect the present invention relates to compositions and methods for the treatment and prevention of disease in a mammal comprising administering the compounds of the invention in a pharmaceutically acceptable form to a mammal. In particular, the invention relates to medicaments comprising various novel substituted dipeptide derived nitrogen-containing heterocyclic compounds and pharmaceutically acceptable salt derivatives and methods for administration to a mammal for the treatment and prevention of malarial diseases. The compounds of the invention may optionally be administered with at least one pharmaceutically acceptable excipient, another biologically active agent or a combination thereof.